Physician profile
Joseph Perez
NPI 1194703595
$4,562.67
in general payments reported to CMS, 2019-2025
31 companies · $626 in 2025
The $626 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $369 · 2021: $871 · 2022: $372 · 2023: $753 · 2024: $589 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,967.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $593.34 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $477.91 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $387.69 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $350.90 | 2022-2025 | Verquvo |
| Amgen INC. | $315.32 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $272.22 | 2019-2025 | Watchman Access System, Watchman Flx |
| Pfizer INC. | $260.53 | 2019-2025 | |
| Abbott Laboratories | $206.78 | 2022-2024 | Jot Dx |
| Amarin Pharma, INC. | $194.06 | 2019-2021 | |
| Medtronic, INC. | $170.91 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $146.49 | 2019-2023 | Farxiga |
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| Recor Medical INC | $104.67 | 2024 | Paradise Renal Denervation System |
| Esperion Therapeutics, INC. | $102.93 | 2020-2025 | Nexletol |
| Abiomed | $93.79 | 2024-2025 | Impella |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $90.72 | 2024 | |
| Heartflow, INC. | $88.59 | 2023-2025 | Ffrct |
| Regeneron Healthcare Solutions, INC. | $88.05 | 2019-2025 | Evkeeza, Praluent |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $76.10 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.01 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $75.34 | 2019 | |
| Lundbeck LLC | $43.54 | 2019-2020 | |
| Novo Nordisk INC | $34.99 | 2024 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $29.00 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $28.02 | 2023 | Uptravi |
| Arbor Pharmaceuticals, INC. | $28.01 | 2020-2021 | |
| Edwards Lifesciences Corporation | $24.02 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.00 | 2025 | |
| Lilly USA, LLC | $21.36 | 2025 | Zepbound |
| Bard Peripheral Vascular, INC. | $20.81 | 2021 | |
| Medtronic Vascular, INC. | $13.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.